

**BAXTER INTERNATIONAL INC.**  
**Net Sales**  
**Periods Ending March 31, 2010 and 2009**  
**(unaudited)**  
**(\$ in millions)**

	Q1 2010	Q1 2009	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>				
United States	\$610	\$622	(2%)	(2%)
International	752	630	19%	8%
<b>Total</b>	<b>\$1,362</b>	<b>\$1,252</b>	<b>9%</b>	<b>3%</b>
<b>Medication Delivery</b>				
United States	\$579	\$514	13%	13%
International	603	521	16%	3%
<b>Total</b>	<b>\$1,182</b>	<b>\$1,035</b>	<b>14%</b>	<b>8%</b>
<b>Renal</b>				
United States	\$95	\$92	3%	3%
International	489	423	16%	5%
<b>Total</b>	<b>\$584</b>	<b>\$515</b>	<b>13%</b>	<b>5%</b>
<b>Baxter excluding Transfusion Therapies</b>				
United States	\$1,284	\$1,228	5%	5%
International	1,844	1,574	17%	5%
<b>Total</b>	<b>\$3,128</b>	<b>\$2,802</b>	<b>12%</b>	<b>5%</b>
<b>Transfusion Therapies <sup>1</sup></b>				
United States	\$9	\$13	(31%)	(31%)
International	3	9	(67%)	(67%)
<b>Total</b>	<b>\$12</b>	<b>\$22</b>	<b>(45%)</b>	<b>(45%)</b>
<b>Baxter International Inc.</b>				
United States	\$1,293	\$1,241	4%	4%
International	1,847	1,583	17%	5%
<b>Total</b>	<b>\$3,140</b>	<b>\$2,824</b>	<b>11%</b>	<b>5%</b>

<sup>1</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.